Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (24153)	7/19/2007 7:19:54 PM
From: tuck	Read Replies (2) \| Respond to of 52153

Taxol did $111 million in sales last quarter. The taxane market is much larger; there is generic competition, so Sonus will have to show some pretty clear safety/ cost benefit to do well. While doctors and patients will like it for the lower infusion time, NICE and American insurers won't care much about that. Certainly, even with declining sales due to generic competition, a takeout seems plausible, as the MC of the company is only half a year's Taxol sales. But I won't pretend to know how pharmas think in these matters. Why hasn't the drug been partnered? Is it simply Sonus' stated strategy to develop it themselves? Tempted, but I remember CTIC too well. I'm a little gunshy about this sort of thing. Cheers, Tuck